MTIP
FOMX

Magee Thomson Investment Partners’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Magee Thomson Investment Partners’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$0 Sell
79
-48
-38% -$462 ﹤0.01% 112
2016
Q4 		$1K Sell
127
-20
-14% -$188 ﹤0.01% 86
2016
Q3 		$1K Hold
147
– – ﹤0.01% 85
2016
Q2 		$1K Sell
147
-494
-77% -$3.28K ﹤0.01% 80
2016
Q1 		$4K Hold
641
– – ﹤0.01% 85
2015
Q4 		$5K Buy
641
+111
+21% +$830 ﹤0.01% 67
2015
Q3 		$4K Buy
530
+91
+21% +$927 ﹤0.01% 89
2015
Q2 		$4K Buy
+439
New +$4.85K ﹤0.01% 100

Other funds holding FOMX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Magee Thomson Investment Partners's FOMX Position: Q1 2017 in Review

Magee Thomson Investment Partners reduced its Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) stake by 38% in Q1 2017, selling an estimated $462 and leaving 79 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #112.

Magee Thomson Investment Partners first reported a position in FOMX in Q2 2015 and has held it in 8 quarters since. The position peaked at $5K in Q4 2015. 67 funds tracked by Wall St. Rank hold FOMX as of Q1 2017.

  • Magee Thomson Investment Partners held 79 shares of Foamix Pharmaceuticals Ltd. Ordinary Shares worth $0 as of Q1 2017.
  • Magee Thomson Investment Partners sold 48 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2017, an estimated $462.
  • Foamix Pharmaceuticals Ltd. Ordinary Shares made up ﹤0.01% of Magee Thomson Investment Partners's portfolio in Q1 2017, its #112 holding.
  • Magee Thomson Investment Partners first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and has held it in 8 quarters since.
  • Magee Thomson Investment Partners's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $5K in Q4 2015.
  • 67 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2017.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2017, filed 21 Apr 2017.